ALVO Stock Forecast 2025-2026
Distance to ALVO Price Targets
ALVO Price Momentum
10 Quality Stocks Worth Considering Now
Researching Alvotech (ALVO) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ALVO and similar high-potential opportunities.
Latest ALVO Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, ALVO has a neutral consensus with a median price target of $15.00 (ranging from $14.00 to $28.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $8.29, the median forecast implies a 80.9% upside. This outlook is supported by 2 Buy, 2 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ALVO Analyst Ratings
ALVO Price Target Range
Latest ALVO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ALVO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 14, 2025 | UBS | Buy | Initiates | $18.00 | |
| Jul 25, 2024 | Barclays | Balaji Prasad | Overweight | Maintains | $18.00 |
| May 24, 2024 | Barclays | Balaji Prasad | Overweight | Maintains | $22.00 |
| Mar 22, 2024 | Barclays | Balaji Prasad | Overweight | Maintains | $20.00 |
| Jan 29, 2024 | Barclays | Balaji Prasad | Overweight | Upgrade | $17.00 |
| Oct 20, 2023 | Citigroup | Andrew Baum | Neutral | Upgrade | $10.00 |
| Sep 21, 2023 | Barclays | Balaji Prasad | Equal-Weight | Initiates | $10.00 |
| Mar 7, 2023 | Deutsche Bank | Emmanuel Papadakis | Hold | Maintains | $12.00 |
| Sep 7, 2022 | Morgan Stanley | Thibault Boutherin | Equal-Weight | Initiates | $10.00 |
| Sep 6, 2022 | Citigroup | Andrew Baum | Sell | Downgrade | $5.00 |
| Jul 26, 2022 | Citigroup | Andrew Baum | Buy | Initiates | $12.00 |
| Jul 1, 2022 | Deutsche Bank | Hold | Initiates | $0.00 |
Alvotech S.A. (ALVO) Competitors
The following stocks are similar to Alvotech based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Alvotech S.A. (ALVO) Financial Data
Alvotech S.A. has a market capitalization of $2.50B with a P/E ratio of -9.5x. The company generates $491.98M in trailing twelve-month revenue with a -47.1% profit margin.
Revenue growth is +177.4% quarter-over-quarter, while maintaining an operating margin of +9.3% and return on equity of +56.2%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Alvotech S.A. (ALVO) Business Model
About Alvotech S.A.
Develops and commercializes biosimilar medicines.
Alvotech S.A. operates by creating biosimilar medicines that are cost-effective alternatives to existing biologic therapies. The company generates revenue through the commercialization of these products across various therapeutic areas, particularly autoimmunity and oncology, leveraging advanced biotechnology and manufacturing processes.
Based in Reykjavik, Iceland, Alvotech navigates a complex regulatory landscape and enhances its market presence through strategic partnerships with other pharmaceutical companies. As patents on original biologics expire, Alvotech is well-positioned to capitalize on the growing biosimilar market, contributing to healthcare affordability and systemic efficiencies.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1,012
CEO
Mr. Robert Wessman
Country
Luxembourg
IPO Year
2022
Website
www.alvotech.comAlvotech S.A. (ALVO) Latest News & Analysis
New Strong Sell Stocks for April 17th
2 days agoAIRS, XOM, and ALVO have been assigned a Zacks Rank of #5 (Strong Sell) as of April 17, 2025. Investors may consider this rating when making decisions.
AIRS, XOM, and ALVO's addition to the Zacks Rank #5 (Strong Sell) indicates potential underperformance, signaling investors to reassess their positions or strategies in these stocks.
Alvotech (ALVO) Q4 2024 Earnings Call Transcript
23 days agoAlvotech (NASDAQ:ALVO) will host its Q4 2024 earnings conference call on March 27, 2025, at 8:00 AM ET, featuring key executives including CEO Robert Wessman.
Alvotech's Q4 earnings call provides insights into its financial performance and strategic direction, influencing stock valuation and investor sentiment.
Alvotech (NASDAQ: ALVO) has appointed Dr. Balaji V. Prasad as Chief Strategy Officer, enhancing its leadership in biosimilar medicines development.
Dr. Prasad's appointment may signal a strategic shift or new growth initiatives for Alvotech, potentially impacting its market position and future profitability in the biotech sector.
This Is a Test From GlobeNewswire
22 days agoGlobeNewswire issued a test message advising readers to disregard it. No actionable information for investors is contained in this communication.
Disregarding the test notification prevents misinformation, ensuring investors focus on credible updates that could impact market decisions and stock valuations.
Alvotech (NASDAQ: ALVO) reported its 2024 financial results and pipeline updates. A business update call is scheduled for March 27, 2024, at 8:00 am ET.
Alvotech's financial results and pipeline updates can impact stock performance and investor sentiment, influencing market perception of its growth potential in the biotech sector.
Alvotech (NASDAQ: ALVO) reported its 2024 financial results and pipeline updates. A business update call is scheduled for March 27, 2024, at 8:00 am ET.
Alvotech's financial results and pipeline updates can influence stock performance, affecting investor sentiment and potential market valuation. The upcoming call may provide critical insights.
Frequently Asked Questions About ALVO Stock
What is Alvotech S.A.'s (ALVO) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, Alvotech S.A. (ALVO) has a median price target of $15.00. The highest price target is $28.00 and the lowest is $14.00.
Is ALVO stock a good investment in 2025?
According to current analyst ratings, ALVO has 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.29. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ALVO stock?
Wall Street analysts predict ALVO stock could reach $15.00 in the next 12 months. This represents a 80.9% increase from the current price of $8.29. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Alvotech S.A.'s business model?
Alvotech S.A. operates by creating biosimilar medicines that are cost-effective alternatives to existing biologic therapies. The company generates revenue through the commercialization of these products across various therapeutic areas, particularly autoimmunity and oncology, leveraging advanced biotechnology and manufacturing processes.
What is the highest forecasted price for ALVO Alvotech S.A.?
The highest price target for ALVO is $28.00 from at , which represents a 237.8% increase from the current price of $8.29.
What is the lowest forecasted price for ALVO Alvotech S.A.?
The lowest price target for ALVO is $14.00 from at , which represents a 68.9% increase from the current price of $8.29.
What is the overall ALVO consensus from analysts for Alvotech S.A.?
The overall analyst consensus for ALVO is neutral. Out of 5 Wall Street analysts, 2 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $15.00.
How accurate are ALVO stock price projections?
Stock price projections, including those for Alvotech S.A., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.